Neutralization of pathogenic PC-OxPL by AAV-delivered scFv as a therapeutic strategy for amyotrophic lateral sclerosis
Molecular Therapy Advances · 2026-09 · 34 (3) · 201822
DOI: 10.1016/j.omta.2026.201822 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Advances, 2026-09. Verfasst von Andreia Gomes-Duarte und 13 weiteren Autor:innen. Beteiligte Einrichtung: VectorY Therapeutics, Science Park 408, Matrix Innovation Center VI, 1098 XH Amsterdam, the Netherlands. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder defined by progressive motor neuron loss and TDP-43 proteinopathy, yet the upstream drivers of this pathology remain unclear. Oxidized phosphatidylcholines (PC-OxPL) have emerged as potent inducers of proteinopathy in the central nervous system (CNS), but their role in ALS has not been systematically explored. We identify a distinct PC-OxPL signature in the cerebrospinal fluid (CSF) of patients with sporadic ALS (sALS) and show that apolipoprotein E (apoE)-containing particles are the primary PC-OxPL carriers in this compartment. In human iPSC-derived motor neurons, PC-OxPL exposure triggered disease-relevant transcriptional alterations and TDP-43 pathology, establishing PC-OxPL as a mediator of ALS-like neurodegeneration in vitro. To counteract this toxicity, we engineered an Adeno-Associated Virus (AAV)-delivered single-chain antibody fragment (scFv), PC-OxPL-VecTab, targeting PC-OxPL neoepitopes. PC-OxPL-VecTab neutralized PC-OxPL-induced neurotoxicity, reduced TDP-43 aggregation, and prevented motor neuron death and behavioral deficits in a sALS CSF transfer mouse model. Intrathecal delivery of PC-OxPL-VecTab in minipigs achieved broad CNS biodistribution and transgene expression, supporting the feasibility of CNS delivery. These findings position PC-OxPL as a mechanistic contributor to ALS pathogenesis and establish PC-OxPL-VecTab as a therapeutic strategy for ALS with potential broader applicability to disorders associated with PC-OxPL accumulation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- VectorY Therapeutics, Science Park 408, Matrix Innovation Center VI, 1098 XH Amsterdam, the Netherlands.
- Tisch Multiple Sclerosis Research Center of New York, 521 West 57th Street, 4th Floor, New York, NY 10019, USA.
- Center for Proteomics and Metabolomics, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands.
- Department of Cardiology, University of California, San Diego, La Jolla, CA 92037, USA.
Zitieren
APA
Gomes-Duarte, A., Wong, J. K., Moro, A., Pasteuning-Vuhman, S., Pos, W., Haselberg, R., Sogorb-González, M., Pascoal, S., Borst, L., Chatterjee, M., Giera, M., Tsimikas, S., Sadiq, S. A., & van Deventer, S. (2026). Neutralization of pathogenic PC-OxPL by AAV-delivered scFv as a therapeutic strategy for amyotrophic lateral sclerosis. Molecular Therapy Advances, 34(3), 201822. https://doi.org/10.1016/j.omta.2026.201822
Vancouver
Gomes-Duarte A, Wong JK, Moro A, Pasteuning-Vuhman S, Pos W, Haselberg R, et al. Neutralization of pathogenic PC-OxPL by AAV-delivered scFv as a therapeutic strategy for amyotrophic lateral sclerosis. Molecular Therapy Advances. 2026;34(3):201822. doi:10.1016/j.omta.2026.201822
BibTeX
@article{GomesDuarte2026,
author = {Gomes-Duarte, Andreia and Wong, Jamie K and Moro, Alessandro and Pasteuning-Vuhman, Svetlana and Pos, Wouter and Haselberg, Rob and Sogorb-González, Marina and Pascoal, Sofia and Borst, Linda and Chatterjee, Madhurima and Giera, Martin and Tsimikas, Sotirios and Sadiq, Saud A and van Deventer, Sander},
title = {Neutralization of pathogenic PC-OxPL by AAV-delivered scFv as a therapeutic strategy for amyotrophic lateral sclerosis},
journal = {Molecular Therapy Advances},
year = {2026},
volume = {34},
number = {3},
pages = {201822},
doi = {10.1016/j.omta.2026.201822}
}
EUVIMED